TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company focused on RNA-based therapeutics for cancer, announced today the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University. The initiatives are designed to bolster the company's pipeline, particularly its lead candidate TTX-MC138, which targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis.
The sponsored research agreement with Michigan State University will support the development of TTX-MC138, including evaluation in combination with other therapies. This collaboration aims to accelerate the progress of TransCode's therapeutic pipeline, which includes other first-in-class candidates designed to mobilize the immune system to recognize and destroy cancer cells. The agreement underscores the company's commitment to advancing treatments for high-risk and advanced cancers.
Dr. Moore brings extensive expertise to her new role as Chair of the Scientific Advisory Board. She will provide strategic guidance on research and development efforts, focusing on advancing the company's RNA-based therapeutic candidates. Her appointment is expected to enhance TransCode's scientific leadership as it progresses its clinical programs.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA-based therapies for the treatment of high-risk and advanced cancers. The company's lead candidate, TTX-MC138, is designed to treat metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells.
This announcement is significant for the biotech industry and for patients battling advanced cancers. The focus on RNA-based therapeutics represents a promising avenue for treating metastatic disease, which remains a major challenge in oncology. By combining the expertise of Dr. Moore and the resources of Michigan State University, TransCode is positioning itself to potentially accelerate the development of novel treatments that could improve outcomes for patients with high-risk cancers.
For more information on the press release, visit https://ibn.fm/NA2NH. The latest news and updates relating to TransCode Therapeutics are available in the company's newsroom at https://ibn.fm/RNAZ.
